We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Humans Can Acquire Immunity to Hepatitis C

By Biotechdaily staff writers
Posted on 24 May 2002
A study has found that humans can acquire immunity to the hepatitis C virus (HCV), suggesting that vaccines could be used to protect those with the virus from long-term complications. More...
Conducted by researchers at Johns Hopkins Medical School (Baltimore, MD, USA), the study was published in the April 26, 2002, issue of The Lancet.

The researchers compared the incidence and persistence of HCV in 164 people whose blood tests revealed no evidence of prior HCV infection and 98 people who had been infected in the past but were not infected at the time of the study. Previously infected people were almost half as likely to develop new infections as those never infected (12% vs 21%). Among HIV-1 negative people, those previously infected were 12 times less likely to develop infection than those infected for the first time. The results mirrored those of chimpanzee studies, which found that animals previously infected or vaccinated could be re-infected but their infections were less likely to persist, compared to animals infected for the first time.

"Our findings indicate that vaccines should be developed to reduce the burden of liver disease associated with hepatitis C infection,” said David. L. Thomas, associate professor of medicine at Hopkins and lead author of the study. About 170 million people worldwide have been infected with HCV, and about 85% of them develop persistent infection and are at risk of serious complications such as liver cirrhosis and liver cancer, according to Dr. Thomas. Recent vaccine research in primates is showing promise.




Related Links:
Johns Hopkins

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
Clinical Informatics Platform
CLARION™
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.